This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through November 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Stock Reports for Merck, Caterpillar & Union Pacific
by Mark Vickery
Merck, Caterpillar and Union Pacific benefit from strong demand, strategic growth drivers and solid cash generation, but face key competitive and execution risks.
CATNegative Net Change MRKNegative Net Change UNPPositive Net Change DJCONegative Net Change CMTVPositive Net Change EMENo Net Change IDXXPositive Net Change GEHCPositive Net Change
consumer-staples finance industrial-products pharmaceuticals transportation
Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?
by Ekta Bagri
MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
BMYNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
by Zacks Equity Research
REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.
REGNNegative Net Change SNYNegative Net Change CTMXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
by Zacks Equity Research
Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
NVSNegative Net Change VCELPositive Net Change ETONNegative Net Change
pharmaceuticals
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
by Kanishka Das
MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
MRKNegative Net Change RHHBYNegative Net Change BMYNegative Net Change MRNANegative Net Change
pharmaceuticals
Revolution Medicines Wins EU Nod for Rasonque in Pancreatic Cancer
by Zacks Equity Research
RVMD secures European Commission approval for Rasonque in metastatic pancreatic cancer, expanding its reach after a strong U.S. launch.
RVMDNegative Net Change BMYNegative Net Change SMMTNegative Net Change TNGXNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Did AbbVie's Neuroscience Franchise Perform in Q3?
by Sundeep Ganoria
ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.
ABBVNegative Net Change BIIBPositive Net Change JNJNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
by Kinjel Shah
AZN's 16 blockbuster drugs, strong oncology sales and pipeline opportunities support its $80B revenue target, despite generic pressure and clinical setbacks.
AZNNegative Net Change JNJNegative Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
J&J to Acquire Ollin Biosciences: A Look at Its Recent Buyouts
by Kinjel Shah
J&J's $2.2 billion Ollin Biosciences deal adds a promising retinal disease candidate, building on acquisitions.
JNJNegative Net Change LLYNegative Net Change GILDNegative Net Change ABBVNegative Net Change
pharmaceuticals
J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition
by Zacks Equity Research
JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.
JNJNegative Net Change COLLPositive Net Change VCELPositive Net Change
pharmaceuticals